Difference between revisions of "Tenofovir/emtricitabine"
m (Date maintenance tags and general fixes: build 422:) |
m (1 revision) |
(No difference)
| |
Latest revision as of 14:07, 6 July 2010
| Combination of | |
|---|---|
| Tenofovir | Nucleotide analogue reverse transcriptase inhibitor |
| Emtricitabine | Nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| Legal status | |
| Legal status | |
| Identifiers | |
| ATC code | J05AR03 (WHO) |
| PubChem | CID 11954236 |
Tenofovir/emtricitabine trademark Truvada, is a fixed dose combination of two antiretroviral drugs used for the treatment of HIV. It consists of 300 milligrams of tenofovir and 200 milligrams of emtricitabine. By combining the two agents into one tablet, it reduces the pill burden and increases compliance with antiretroviral therapy. The drug has also found some potential as a preventative measure if taken daily or weekly leading up to exposure, though human clinical trials are ongoing [1][2].
Clinical Studies
The HEAT study (Randomized, double-blind, placebo-matched, multicentre)showed that once-daily emtricitabine/tenofovir plus lopinavir/ritonavir or boosted atazanavir or efavirenz were effective in the initial treatment of patients with HIV-1 infection (with screening plasma HIV-1 RNA levels of <math>>=</math>1000000copies/mL in ACTG 5202).[1] In other randomized studies, emtricitabine/tenofovir DF 200 mg/300 mg once daily was an effective backbone for boosted PI-based regimens in the initial treatment of HIV-1 infection.[1] Emtricitabine/tenofovir DF in combination with various boosted PIs was generally well tolerated by adults with HIV-1 infection.[1]
Truvada was developed by Gilead Sciences and approved by the Untited States' Food and Drug Administration in 2004.
A combination pill containing Truvada and efavirenz (Sustiva) is also available and is marketed as Atripla.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />- Truvada website, run by Gilead Sciences
- Global iPrEx study website, medication info page
Please help improve this article by expanding it. Further information might be found on the talk page. (June 2010) |
- Pages with script errors
- Drugs that are a combination of chemicals
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Pages with broken file links
- Articles to be expanded from June 2010
- Articles with invalid date parameter in template
- All articles to be expanded
- Gilead Sciences
- Fixed dose combination (antiretroviral)
- World Health Organization essential medicines
- 2Fix
